[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0262119A1 - Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody - Google Patents

Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody

Info

Publication number
EP0262119A1
EP0262119A1 EP86901744A EP86901744A EP0262119A1 EP 0262119 A1 EP0262119 A1 EP 0262119A1 EP 86901744 A EP86901744 A EP 86901744A EP 86901744 A EP86901744 A EP 86901744A EP 0262119 A1 EP0262119 A1 EP 0262119A1
Authority
EP
European Patent Office
Prior art keywords
epf
antibody
cells
serum
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86901744A
Other languages
German (de)
French (fr)
Other versions
EP0262119A4 (en
Inventor
Halle Morton
Alice Christina Cavanagh
Barbara Ellen Rolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of EP0262119A4 publication Critical patent/EP0262119A4/en
Publication of EP0262119A1 publication Critical patent/EP0262119A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein

Definitions

  • This invention relates to a method for detecting early pregnancy factor (EPF) in mammals, purifying EPF and a method for producing a monoclonal antibody therefor.
  • Pregnancy involves two early important milestones - fertilization of the ovum and implantation of the fertilized ovum in the uterus approximately eight-ten days after fertilization.
  • the present invention resides in a method for producing EPF from any mammalian cell source including the steps of: growing a selected cell which produces EPF in a culture medium to produce a supernatant medium containing EPF and other products; and harvesting the supernatant medium to obtain the EPF.
  • the present invention resides in a method for purifying EPF including the steps of: passing a supernatant medium containing EPF through a column containing a selective absorbent for the EPF (i.e. immuno absorption of the EPF); eluting the EPF from the selective absorbent to produce a first eluate; effecting reversed phase high performance liquid chromotography (HPLC) on the first eluate in a column; and eluting the bound EPF from the column to collect the purified EPF.
  • a selective absorbent for the EPF i.e. immuno absorption of the EPF
  • HPLC reversed phase high performance liquid chromotography
  • the first eluate is dialysed against a buffer solution to remove any small molecular weight products; the dialysis product is concentrated; gel filtration is effected on the concentrate; and selected fractions of the filtrate are collected and the reversed phase high performance chromotography is effected on the collected fractions.
  • the present invention resides in a method for producing monoclonal antibodies to EPF including the steps of: immunizing an animal with purified EPF; removing the spleen of the animal and fusing the spleen cells with selected cells; growing the fused cells in a culture medium; selecting the hybrid (fused) cells from the non-fused cells; and cloning out the hybrid cells producing the EPF antibody by limiting dilution methods.
  • the hybrid cells may be grown in a culture medium (i.e. in vitro) to produce high concentrations of monoclonal antibody to EPF, or in BALB/C mice (i.e. in vivo) and harvesting from these mice serum and/or ascites which will contain high concentrations of monoclonal antibody to EPF.
  • the present invention resides in a method for pregnancy diagnosis in a female mammal including the steps of: mixing EPF antibodies with serum or urine believed to contain EPF; and monitoring any reaction due to the presence of EPF in the serum or urine.
  • Human EPF was produced by continuously growing Choriocarcinoma cells (sold under the trade mark "Be Wo” by the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. and deposited under ATCC Deposit No. CCL98), human myeloma cells (ATCC Deposit No. CCL 155) or human lymphoblastic leukemia cells (ATCC Deposit No. CRL 1582) in culture medium comprising "DMEM” ( "Dulbecco's Modification of Eagle's Medium”) (sold by Flow Laboratories Inc., 7655 Old Springhouse Road, McLean, VA 22102, U.S.A. and subsidiary companies in. inter alia Australia, Canada, Japan, the United Kingdom and Sweden), and foetal calf serum (sold by Commonwealth Serum Laboratories, Melbourne, Australia) and harvesting the supernatant medium. This supernatant medium contains human EPF and other products.
  • DMEM "Dulbecco's Modification of Eagle's Medium”
  • An immuno-absorption column is prepared using goat/anti-mouse EPF (or any other suitable EPF e.g. using rabbits or donkeys as the host for mouse, human or rat EPF).
  • anti-EPF IgG immunoglobulin
  • human serum and with foetal calf serum bound to cyanogen bromide activated Sepharose 4B (sold under the trade name
  • the supernatant medium, containing the EPF, is pumped through the column and the human EPF will bind to the anti-mouse EPF in the absorption column, the latter acting as a selective absorber of the human EPF.
  • the human EPF is eluted with 1M acetic acid/ 0.9% NaC1/10% dioxane and the eluate is dialysed and the buffer is exchanged for 1M acetic acid adjusted to pH3.0 by ammonium hydroxide to remove small molecular weight products. (All percentages are expressed as "%(w/v) or (v/v)").
  • the product is concentrated to a 3mL. volume and undergoes gel filtration in a column of Sephacryl S-200 (supplied by Pharmacia Biotechnology Products, Sweden - see page 84 of their"Catalogue 86")which has been equilibrated with 1M acetic acid adjusted to pH3.0 with ammonium hydroxide.
  • This sample is filtered on the basis of molecular size and, on a 16mm. x 900mm. column, collecting 2mL. fractions, fractions 60-80 (i.e. 120-160mL. flow) contain the EPF. These are pooled and TFA (trifluroacetic acid) added to a final concentration of 0.1%.
  • TFA trifluroacetic acid
  • the mixture is applied to a Beckman RPSC ultrapore reversed phase HPLC column (e.g. 4.6mm. x 75mm.) which has been equilibrated with 0.1% TFA.
  • a Beckman RPSC ultrapore reversed phase HPLC column e.g. 4.6mm. x 75mm.
  • the bound EPF is eluted with a 2 minute linear gradient to 25% isopropanol followed by a 30 minute linear gradient to 30% isopropanol both containing 0.1% TFA at a flow rate of 1mL. /minute.
  • the fractions eluted with retention times between 9.8 - 11.3 minutes contain the purified EPF. These fractions are pooled and stored. With some immunoabsorbents, it is possible to omit the dialysis and gel filtration steps and apply the eluate directly to the reversed phase HPLC column (which has been equilibrated with 0.1% TFA), after addition of TFA to a final concentration of 0.1%.
  • BALB/c mice e.g.
  • mice bred from BALB/cJ strain mice from The Jackson Laboratory, Bar Harbor, Maine, 04609, U.S.A.
  • EPF purified EPF
  • the spleens were removed and the spleen cells were fused with mouse myeloma cells (e.g. catalogue Nos. X63-Ag8-653 or Sp2/0-Ag-l4 from Flow Laboratories Australasia Pty. Ltd., 140 Wicks Road, North Ryde, Sydney, N.S.W. 2113, Australia).
  • the cells are grown in "DMEM" medium with 2mM fresh L-glutamine,20% foetal calf serum plus antibiotics and fungicides, and the hybrid cells selected by addition of HAT medium (containing
  • the hybrid cells are cloned out by limiting dilution techniques and are tested to establish which clones produce an antibody to EPF.
  • the hybrid cells may be grown in a culture medium (i.e. in vitro) to produce high concentrations of monoclonal antibody to EPF, or in BALB/c mice (i.e. in vivo) and harvesting from these mice serum and/or ascites which will contain high concentrations of monoclonal antibody to EPF. Those cells are recloned until a cell producing a monoclonal antibody is achieved. Samples of clones in intermediate or final stages are stored in liquid N 2 .
  • the resultant product can be used to detect EPF in human serum or urine for pregnancy diagnosis.
  • EPF including some labelled with [ 125 I] is mixed with anti-EPF antibody and the mixture is allowed to react to produce a complex.
  • the complex is precipitated by adding a precipitating antibody or polyethylene glycol.
  • a negative sample i.e. no EPF in the serum
  • a positive sample containing EPF
  • the labelled EPF and the antibody will result in a low ⁇ count. This is due to competitive binding between the EPF and labelled EPF with the antibody, as the EPF will prevent the labelled EPF from binding.
  • two different antibodies to EPF may be used, the antibodies binding to different sites on the EPF molecule.
  • One antibody is placed in a plastic tube or on polystyrene beads or sticks and allowed to bind.
  • the serum is added to the tube or placed in contact with the beads or sticks and EPF therein is allowed to bind with the first antibody.
  • a second antibody, labelled with Iodine 125, is then allowed to bind with EPF.
  • the bound Iodine 125 is counted with a ⁇ -counter and a high count indicates the presence of EPF.
  • This method would be particularly suitable for a home pregnancy testing kit where the first antibody is bound on a testing stick which is dipped into the female's urine specimen and then into a first container supplied with the kit containing the second antibody labelled with an enzyme which undergoes a colour change when the stick dipped into a second container supplied with the kit containing a suitable substrate.
  • the embodiments described above are specific and that a range of chemical proportions and times may be used.
  • the gel filtration may be carried out using "Sephadex G-100" (see page 80 of the Pharmacia Biotechnology Products "Catalogue 86”) equilibrated with 1M acetic acid pH2.5.
  • the methods are suitable for the EPF of all mammalian animals.
  • the method for detecting pregnancy can be extremely important in the horse and cattle industries and in the preservation of endangered species.
  • the giant panda gives no indication of pregnancy but pregnancy could be determined, with out handling the female, by collecting urine e.g. from the cage floor, and assaying with the particular suitable monoclonal antibody.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des cellules produisant de l'EPF sont cultivées dans un milieu de culture afin de produire un milieu surnageant contenant de l'EPF. Pour purifier l'EPF, celui-ci est absorbé par un absorbant sélectif dans une colonne, dialysé dans une solution tampon, concentré et filtré à travers un gel. Des parties sélectionées du filtrat sont soumises à une chromatographie liquide à phase inversée de haute performance, et l'EPF purifié est obtenu par élution de la colonne chromatographique. Il est possible de produire des anticorps monoclonaux de l'EPF pour détecter la présence d'EPF dans du sérum et fournir un moyen de détection de la grossesse ches des mammifères du sexe féminin.Cells producing EPF are cultured in a culture medium in order to produce a supernatant medium containing EPF. To purify the EPF, it is absorbed by a selective absorbent in a column, dialyzed in a buffer solution, concentrated and filtered through a gel. Selected parts of the filtrate are subjected to high performance reverse phase liquid chromatography, and the purified EPF is obtained by elution from the chromatographic column. Monoclonal EPF antibodies can be produced to detect the presence of EPF in serum and provide a means of detecting pregnancy in female mammals.

Description

Title: "METHOD FOR DETECTING EARLY PREGNANCY FACTOR (EPF) IN MAMMALS, PURIFYING EPF AND METHOD FOR PRODUCING A MONOCLONAL ANTIBODY" BACKGROUND OF THE INVENTION (1) Field of the Invention
This invention relates to a method for detecting early pregnancy factor (EPF) in mammals, purifying EPF and a method for producing a monoclonal antibody therefor. (2) Prior Art
Most home pregnancy kits can only detect and indicate pregnancy approximately 3-4 weeks after fertilization.
Pregnancy involves two early important milestones - fertilization of the ovum and implantation of the fertilized ovum in the uterus approximately eight-ten days after fertilization.
It would greatly assist research if the precise times that both milestones occurred could be detected. It would also be an advantage if a woman was aware she was pregnant immediately after fertilization so that she could avoid e.g. smoking, alcohol, surgery and x-rays or radiation treatment.
It has been established that EPF is produced within 24 hours of fertilization but the problem has been to isolate the EPF protein, purify it and produce an antibody which can be used to detect the presence of EPF e.g. in serum or urine as a test for pregnancy. BRIEF SUMMARY OF THE INVENTION
With the above matter in mind, preferred objects of the present invention are to achieve methods to overcome each of the problems hereinbefore described. In one aspect the present invention resides in a method for producing EPF from any mammalian cell source including the steps of: growing a selected cell which produces EPF in a culture medium to produce a supernatant medium containing EPF and other products; and harvesting the supernatant medium to obtain the EPF.
In a second aspect the present invention resides in a method for purifying EPF including the steps of: passing a supernatant medium containing EPF through a column containing a selective absorbent for the EPF (i.e. immuno absorption of the EPF); eluting the EPF from the selective absorbent to produce a first eluate; effecting reversed phase high performance liquid chromotography (HPLC) on the first eluate in a column; and eluting the bound EPF from the column to collect the purified EPF. Preferably the first eluate is dialysed against a buffer solution to remove any small molecular weight products; the dialysis product is concentrated; gel filtration is effected on the concentrate; and selected fractions of the filtrate are collected and the reversed phase high performance chromotography is effected on the collected fractions.
In a third aspect the present invention resides in a method for producing monoclonal antibodies to EPF including the steps of: immunizing an animal with purified EPF; removing the spleen of the animal and fusing the spleen cells with selected cells; growing the fused cells in a culture medium; selecting the hybrid (fused) cells from the non-fused cells; and cloning out the hybrid cells producing the EPF antibody by limiting dilution methods. The hybrid cells may be grown in a culture medium (i.e. in vitro) to produce high concentrations of monoclonal antibody to EPF, or in BALB/C mice (i.e. in vivo) and harvesting from these mice serum and/or ascites which will contain high concentrations of monoclonal antibody to EPF.
In a fourth aspect the present invention resides in a method for pregnancy diagnosis in a female mammal including the steps of: mixing EPF antibodies with serum or urine believed to contain EPF; and monitoring any reaction due to the presence of EPF in the serum or urine.
DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT To enable the invention to be fully understood, a preferred example will be described with reference to human EPF.
Human EPF was produced by continuously growing Choriocarcinoma cells (sold under the trade mark "Be Wo" by the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. and deposited under ATCC Deposit No. CCL98), human myeloma cells (ATCC Deposit No. CCL 155) or human lymphoblastic leukemia cells (ATCC Deposit No. CRL 1582) in culture medium comprising "DMEM" ( "Dulbecco's Modification of Eagle's Medium") (sold by Flow Laboratories Inc., 7655 Old Springhouse Road, McLean, VA 22102, U.S.A. and subsidiary companies in. inter alia Australia, Canada, Japan, the United Kingdom and Sweden), and foetal calf serum (sold by Commonwealth Serum Laboratories, Melbourne, Australia) and harvesting the supernatant medium. This supernatant medium contains human EPF and other products.
An immuno-absorption column is prepared using goat/anti-mouse EPF (or any other suitable EPF e.g. using rabbits or donkeys as the host for mouse, human or rat EPF).
To prepare the column, 800mg. of anti-EPF IgG (immunoglobulin) is absorbed with human serum and with foetal calf serum bound to cyanogen bromide activated Sepharose 4B (sold under the trade name
"CNBr-activated Sepharose 4B" by Pharmacia Biotechnology Products, Sweden - see page 91 of their "Catalogue 86") and the absorbed IgG is bound to 30mL of "Affigel-10" (trade name of Bio-Rad, 2200 Wright Avenue, Richmond CA 94804, U.S.A. and subsidiary companies in, inter alia, Australia, Canada, Japan, the United Kingdom and Switzerland. "Affigel-10" is detailed at pages 46-51 of the Bio-Rad Catalogue No. K1985). A pre-column is placed in series with the absorption column having 4g. of IgG from normal male goat serum bound to 100mL. of Affigel-10.
The supernatant medium, containing the EPF, is pumped through the column and the human EPF will bind to the anti-mouse EPF in the absorption column, the latter acting as a selective absorber of the human EPF. The human EPF is eluted with 1M acetic acid/ 0.9% NaC1/10% dioxane and the eluate is dialysed and the buffer is exchanged for 1M acetic acid adjusted to pH3.0 by ammonium hydroxide to remove small molecular weight products. (All percentages are expressed as "%(w/v) or (v/v)").
The product is concentrated to a 3mL. volume and undergoes gel filtration in a column of Sephacryl S-200 (supplied by Pharmacia Biotechnology Products, Sweden - see page 84 of their"Catalogue 86")which has been equilibrated with 1M acetic acid adjusted to pH3.0 with ammonium hydroxide.
This sample is filtered on the basis of molecular size and, on a 16mm. x 900mm. column, collecting 2mL. fractions, fractions 60-80 (i.e. 120-160mL. flow) contain the EPF. These are pooled and TFA (trifluroacetic acid) added to a final concentration of 0.1%.
The mixture is applied to a Beckman RPSC ultrapore reversed phase HPLC column (e.g. 4.6mm. x 75mm.) which has been equilibrated with 0.1% TFA.
The bound EPF is eluted with a 2 minute linear gradient to 25% isopropanol followed by a 30 minute linear gradient to 30% isopropanol both containing 0.1% TFA at a flow rate of 1mL. /minute.
With the inclusion of a 2mL sample loop in the solvent path of the columns, the fractions eluted with retention times between 9.8 - 11.3 minutes contain the purified EPF. These fractions are pooled and stored. With some immunoabsorbents, it is possible to omit the dialysis and gel filtration steps and apply the eluate directly to the reversed phase HPLC column (which has been equilibrated with 0.1% TFA), after addition of TFA to a final concentration of 0.1%. To produce the monolconal antibodies to the human EPF, BALB/c mice (e.g. bred from BALB/cJ strain mice from The Jackson Laboratory, Bar Harbor, Maine, 04609, U.S.A.) were immunized with the purified EPF e.g. with 4 to 5 injections at monthly intervals. The spleens were removed and the spleen cells were fused with mouse myeloma cells (e.g. catalogue Nos. X63-Ag8-653 or Sp2/0-Ag-l4 from Flow Laboratories Australasia Pty. Ltd., 140 Wicks Road, North Ryde, Sydney, N.S.W. 2113, Australia). The cells are grown in "DMEM" medium with 2mM fresh L-glutamine,20% foetal calf serum plus antibiotics and fungicides, and the hybrid cells selected by addition of HAT medium (containing
10 -4M hypoxanthine/4 x 10-7M aminopterin/1.6 x 10-5M Thymidine).
The hybrid cells are cloned out by limiting dilution techniques and are tested to establish which clones produce an antibody to EPF. As hereinbefore described, the hybrid cells may be grown in a culture medium (i.e. in vitro) to produce high concentrations of monoclonal antibody to EPF, or in BALB/c mice (i.e. in vivo) and harvesting from these mice serum and/or ascites which will contain high concentrations of monoclonal antibody to EPF. Those cells are recloned until a cell producing a monoclonal antibody is achieved. Samples of clones in intermediate or final stages are stored in liquid N2.
The resultant product can be used to detect EPF in human serum or urine for pregnancy diagnosis.
A number of alternative methods for diagnosing pregnancy through the detection of EPF in serum will now be described.
In a liquid phase method, EPF (including some labelled with [125I] is mixed with anti-EPF antibody and the mixture is allowed to react to produce a complex. The complex is precipitated by adding a precipitating antibody or polyethylene glycol.
The presence of any Iodine 125 in the precipitate is monitored using a α-counter.
A negative sample (i.e. no EPF in the serum) plus the labelled EPF and the antibody will result in a high α count while a positive sample (containing EPF) plus the labelled EPF and the antibody will result in a low α count. This is due to competitive binding between the EPF and labelled EPF with the antibody, as the EPF will prevent the labelled EPF from binding.
In a solid phase method, two different antibodies to EPF may be used, the antibodies binding to different sites on the EPF molecule. One antibody is placed in a plastic tube or on polystyrene beads or sticks and allowed to bind. The serum is added to the tube or placed in contact with the beads or sticks and EPF therein is allowed to bind with the first antibody. A second antibody, labelled with Iodine 125, is then allowed to bind with EPF. The bound Iodine 125 is counted with a α -counter and a high count indicates the presence of EPF.
This method would be particularly suitable for a home pregnancy testing kit where the first antibody is bound on a testing stick which is dipped into the female's urine specimen and then into a first container supplied with the kit containing the second antibody labelled with an enzyme which undergoes a colour change when the stick dipped into a second container supplied with the kit containing a suitable substrate.
It will be readily apparent to the skilled addressee that the embodiments described above are specific and that a range of chemical proportions and times may be used. For example, the gel filtration may be carried out using "Sephadex G-100" (see page 80 of the Pharmacia Biotechnology Products "Catalogue 86") equilibrated with 1M acetic acid pH2.5.
While human EPF has been described, the methods are suitable for the EPF of all mammalian animals. In particular the method for detecting pregnancy can be extremely important in the horse and cattle industries and in the preservation of endangered species. For example, the giant panda gives no indication of pregnancy but pregnancy could be determined, with out handling the female, by collecting urine e.g. from the cage floor, and assaying with the particular suitable monoclonal antibody.
Various changes and modifications may be made to the embodiments described without departing from the scope of the present invention defined in the appended claims.

Claims

1. A method for producing early pregnancy factor (EPF) from any mammalion cell source characterised by the steps of: growing a selected cell which produces EPF in a culture medium to produce a supernatant medium containing EPF and other products; and harvesting the supernatant medium to obtain the EPF.
2. A method according to claim 1 characterized in that: to produce human EPF, the selected cells are choriocarcinoma cells, human myeloma cells, human lymphoblastic cells or a combination of two or more of these.
3. A method according to claim 1 characterized in that: to produce human EPF, the culture medium comprises "Dulbecco's Modification of Eagle's Medium" and foetal calf serum.
4. A method for purifying EPF wherein the step of harvesting the supernatant medium to obtain the EPF in claim 1 is characterized by the steps of: passing the supernatant medium through a column containing a selective absorbent for the EPF; eluting the EPF from the selected absorbent to produce a first eluate; effecting reversed phase high performance liquid chromotography on the first eluate in a column; and eluting the bound EPF from the column to collect the purified EPF.
5. A method according to claim 4 characterized in that: the first eluate is dialysed against a buffer solution to remove any small molecular weight products; the dialysis product is concentrated; gel filtration is effected on the concentrate; and selected fractions of the filtrate are collected and the reversed phase high performance chromotography is effected on the collected fractions.
6. A method according to claim 4 characterized in that: for producing human EPF, goat/anti-mouse EPF, goat/anti-human EPF, goat/anti-rat EPF, rabbit/anti-human EPF, rabbit/anti-rat EPF, donkey/anti-mouse EPF, donkey/ anti-human EPF, donkey/anti-rat EPF, mouse/anti-human EPF, or a combination of two or more of these is used as the selective absorbent for the EPF.
7. A method according to claim 4 characterized in that: for producing human EPF, the human EPF is eluted with 1M acetic acid/0.9% NaC1/10% dioxane and the buffer solution is exchanged for 1M acetic acid adjusted to pH3.0 by ammonium hydroxide.
8. A method according to claim 5 characterized in that: the gel filtration is effected in a column containing a gel filtrate equilibrated with 1M acetic acid adjusted to pH3.0.
9. A method according to claim 4 characterized in that: the selected filtration fractions are pooled and trifluroacetic acid is added to a concentration of 0.1%, and applied to a Beckman C3 reversed phase HPLC column which has been equilibrated with 0.1% trifluroacetic acid.
10. A method according to claim 4 characterized in that: the bound EPF is eluted with a 2 minute linear gradient to 25% isopropanol followed by a 30 minute linear gradient to 30% isopropanol both containing 0.1% trifluroacetic acid at a flow rate of 1mL per minute.
11. A method according to claim 9 characterized in that: with the inclusion of a 2mL sample coop in the solvent path of the column, the fractions eluted with retention times between 9.8 - 11.3 minutes contain the purified EPF and these fractions are pooled and stored.
12. A method according to claim 4 characterized in that: trifluroacetic acid to a final concentration of 0.1% is added to the first eluate before the chromotography step; and the chromotography step is effected in a Beckman reversed phase HPLC column which has been equilibrated with 0.1% trifluroacetic acid.
13. A method for producing monoclonal antibodies to EPF characterized by the steps of: immunizing an animal with purified EPF obtained by the method of claim 4; removing the spleen of the animal and fusing the spleen cells with selected cells; growing the fused cells in a culture medium; selecting the fused cells from non-fused cells in a medium; and cloning out the hybrid cells producing the EPF antibody by limiting dilution methods.
14. A method according to claim 13 characterized in that: the hybrid cells are grown in vitro in a culture medium to produce high concentration of monoclonal antibody to EPF.
15. A method according to claim 3 characterized in that: the hybrid cells are grown in vivo in mice and are harvested from the mice serum and/or ascites which contains high concentration of monoclonal antibody to EPF.
16. A method according to claim 13 characterized in that: the animals are mice which are immunized with 4 to 5 injections at monthly intervals.
17. A method according to claim 13 characterized in that: the selected cells are mouse myeloma cells; the culture medium comprises "Dulbecco's Modification to Eagle's Medium", 20% foetal calf serum, antibiotics and fungicides; and the hybrid cells are selected in a HAT medium to kill any background cells.
18. A method according to claim 17 characterized in that: the cloned hybrid cells are tested to establish which clones produce an antibody to EPF; and these cells are recloned until a cell producing a monoclonal antibody is achieved.
19. A method for diagnosing pregnancy in a female mammal characterized by the steps of: mixing antibodies produced by the method of claim 13 with serum or urine of the femal mammal believed to contain EPF; and monitoring any reaction due to the presence of EPF in the serum or urine, the presence of EPF indicating pregnancy in the female mammal.
20. A method according to claim 19 characterized in that: the EPF in the serum or urine is used with an anti-EPF antibody with the addition of a trace amount of purified EPF labelled with Iodine 125; the mixture is allowed to react to form a complex; the complex is preciptiated out; and the presence of any Iodine 125 in the precipitate is monitored using a α-counter, a low αcount indicating the presence of EPF in the serum or urine.
21. A method according to claim 19 characterized in that: a first anti-EPF antibody is bound to a plastic tube, stick or beads; the serum or urine is placed in contact with the first antibody to enable any EPF in the serum or urine to bind with the antibody; a second anti-EPF antibody, labelled with Iodine 125, is placed in contact with the EPF to bind therewith; and the presence of bound Iodine 125 is monitored with a α-counter, a high count indicating the presence of EPF.
22. A method according to claim 19 characterized in that: a first anti-EPF antibody is bound to a plastic stick; the stick is dipped in the serum or urine to enable any EPF therein to bind with the first antibody; and the stick is dipped into a second anti-EPF antibody labelled with an enzyme and then a substrate which undergoes a colour change if EPF is present in the serum or urine.
23. Purified EPF obtained by the method of any one of claims 4 to 12.
24. Monoclonal antibodies to EPF obtained by the method of any one of claims 13 to 18.
25. A pregnancy testing kit for female mammals characterized by: a plastic tube container, stick or beads to which are bonded, a first anti-EPF antibody; a first container containing a second anti-EPF antibody labelled with an enzyme; and a second container containing a substrate, wherein: after serum or urine from the female mammal is placed in the tube, or the stick or beads are dipped in the serum or urine from the female mammal, to enable any EPF therein to bind with the first anti-EPF antibody; and the second anti-EPF antibody and then the substrate are placed in the tube, or the stick or glass beads are dipped in the second anti-EPF antibody and then the substrate, a change of colour of the substrate indicates the presence of EPF in the serum or urine and that the female mammal is pregnant.
EP86901744A 1985-03-12 1986-03-12 Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody Withdrawn EP0262119A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPG966485 1985-03-12
AU9664/85 1985-03-12
AUPG975085 1985-03-15
AU9750/85 1985-03-15
AUPH240285 1985-09-12
AU2402/85 1985-09-12

Publications (2)

Publication Number Publication Date
EP0262119A4 EP0262119A4 (en) 1988-02-08
EP0262119A1 true EP0262119A1 (en) 1988-04-06

Family

ID=27157241

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86901744A Withdrawn EP0262119A1 (en) 1985-03-12 1986-03-12 Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody

Country Status (3)

Country Link
EP (1) EP0262119A1 (en)
GB (1) GB2192634B (en)
WO (1) WO1986005498A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603053A1 (en) * 1986-01-30 1987-08-06 Schering Ag PREGNANCY DETECTION WITH EPF
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland Method of treatment of mammals using antibodies to early pregnancy factor (epf).
EP0733071A4 (en) 1993-11-30 1997-02-26 Univ Queensland Antagonists to chaperonin 10
CA2319417A1 (en) * 1998-02-02 1999-08-05 Concepto Diagnostics, Inc. Method and apparatus for detecting conception in animals
US7034120B2 (en) 1999-02-02 2006-04-25 Edp Biotech Corporation, Inc. Method and apparatus for detecting conception in animals
AU3511900A (en) * 1999-03-02 2000-09-21 Kems Bio-Test Ltd. Bovine pregnancy testing
CN108314732A (en) * 2018-01-15 2018-07-24 妊达（北京）生物技术有限公司 A kind of preparation method of anti-ox early pregnancy factor cell strain of monoclonal antibody monoclonal antibody
CN114894911B (en) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 Method for controlling quality of bovine serum products

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48741A (en) * 1975-12-26 1979-07-25 Rafa Labor Ltd Method for the determination of pregnancy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 170, abstract no. 109441g, Columbus, Ohio, US; A.C. CAVANAGH: "Purification and partial characterization of EPF", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 179-89 *
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 473, abstract no. 112770u, Columbus, Ohio, US; T.K. ROBERTS et al.: "Early pregnancy factor of human urine", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 191-3 *
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 489, abstract 112890h, Columbus, Ohio, US; H. MORTON: "EPF as a pregnancy protein", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 53-64 *
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 85, abstract no. 108668z, Columbus, Ohio, US; M. MESROGLI et al.: EPF as a marker for fertilization and implantation in the human", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 233-5 *
See also references of WO8605498A1 *

Also Published As

Publication number Publication date
WO1986005498A1 (en) 1986-09-25
GB2192634A (en) 1988-01-20
EP0262119A4 (en) 1988-02-08
GB2192634B (en) 1990-03-21
GB8720636D0 (en) 1987-10-07

Similar Documents

Publication Publication Date Title
Lindstrom et al. [29] Production and assay of antibodies to acetylcholine receptors
DE3888224T2 (en) Determination of tumor necrosis factor; monoclonal antibody and composition.
Goding Use of staphylococcal protein A as an immunological reagent
US4578335A (en) Interleukin 2 receptor
US4423147A (en) Monoclonal antibody to interferon-α
CA1247539A (en) Method for detecting immune complexes in serum
JP2617289B2 (en) Monoclonal antibody-producing hybridoma cell line
Bazin et al. Rat monoclonal antibodies. II. A rapid and efficient method of purification from ascitic fluid or serum
CA1290266C (en) Monoclonal antibodies to unreduced nonenzymatically glycated proteins
US4784942A (en) Monoclonal antibodies against autoimmune RNA proteins
Wall et al. Binding and release of factor VIII/von Willebrand's factor by human endothelial cells
EP0262119A1 (en) Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
JPH0611235B2 (en) Monoclonal antibody
Harford et al. Immunological approaches to the study of membrane receptors. A monoclonal antibody that inhibits the binding of asialoglycoproteins to the rat liver receptor.
US4299814A (en) Radioimmunoassay of MIF
NO303693B1 (en) Pure human corboxy-terminal propeptide of type I procollagen, antibody and use of antibody produced thereto, and assay kit comprising the antibody
EP0122628A2 (en) Monoclonal antibodies to human immune interferon
EP0506523A2 (en) Monoclonal antibodies
Stenman et al. Characterization of a monoclonal antibody to human alpha-fetoprotein and its use in affinity chromatography
AU599021B2 (en) Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
US5264351A (en) Monoclonal antibodies against autoimmune RNA proteins
CN115677856B (en) Anti-human IgM antibodies and uses thereof
US4803167A (en) Monoclonal antidigoxtin antibodies
JPS6070360A (en) Acceptor measuring method using monochronal antibody with anti-idiosyncratic mark
DE68917797T2 (en) Monoclonal antibodies specific for human fibrinopepid A.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR IT LI NL SE

17Q First examination report despatched

Effective date: 19900928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920714

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CAVANAGH, ALICE, CHRISTINA

Inventor name: MORTON, HALLE

Inventor name: ROLFE, BARBARA, ELLEN